polaprezinc Report issue

Small molecule Experimental
AACT DrugBank Drug Central MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Zinc L-carnosine, often simply called zinc carnosine, and also known as polaprezinc, is a mucosal protective chelate compound of zinc and L-carnosine invented by Hamari Chemicals, Ltd. It is a quadridentate 1:1 complex of a polymeric nature. Although it contains 23% zinc and 77% L-carnosine by mass, zinc carnosine is a molecule and not a mixture of zinc and L-carnosine.   Wikipedia

Chemistry

  • SMILES: NCCC(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O
  • InChIKey: CQOVPNPJLQNMDC-ZETCQYMHSA-N
  • Mol. Mass: 226.24
  • ALogP: -1.13
  • ChEMBL Molecule:
    polaprezinc  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

ahz-zinc | beta-alanyl-l-histidinato zinc | n-(3-aminopropionyl)-l-histidinato zinc | polaprezinc | z 103 | z-103 | zinc carnosine | zinc l-carnosine | zinc l-carnosine complex | zinc n-(3-aminopropionyl)histidine

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Healthy Volunteers (Phase 1)

Pain (Phase 3)

Periodontal Index (Phase 3)

Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue